Doing a dividend discount model on TASR using a generous 30% growth in EPS for 4 years, a discount rate of 10% (what I would like to earn on my investment in a risky asset), a zero dividend payout, and assuming I can sell the stock in 4 years at a PE multiple of 25 times, the net present value of the stock is $15. Currently, the stock has a multiple of 40 and a PEG ratio exceeding 2. Why do you think it should go up?
It would be helpful if you relied on reality. TASR does not get a majority of its revenue and profit from cameras.
Anyone could make money shorting the biotech sector over the last few months. The sector may have bottomed. Be careful. OSIR is making money, which is more than anyone can say about other small biotechs (the "promise" only holds on a while).
TASR's Form 10-K states that Evidence captures, stores and manages video. But what does TASR mean by "manage"? In a Tuesday, 2/2/16 article in the L.A. Times, the Deputy DA for San Diego County says he and others have "spent nearly two years trying to figure out the most efficient ways to collect, categorize, review and store the video." And some, if not all, public agencies in San Diego with body cameras (San Diego, Chula Vista, Coronado and Escondido PDs, San Diego Metro and Southwestern College) use Evidence. The DA office expect to receive upwards of 100,000 videos from police body cameras this year. Just how effective is TASR's training program if these people in San Diego have been working with Evidence for two years? Does it involve adequate categorization and retrieval training? And I recall another L.A. Times article from last year mentioning LAPD's police chief stating they were looking for software to handle the video. Obviously, TASR's "complete" system isn't there yet. And we all have experienced difficulty in finding something we stored previously. Time for IBM's software to step up to the plate.
Companies have 90 days to report yearly results. If they go past March 31, then be concerned. Until then, hold your shirt.
It will return in ways they don't expect. Prospective employers review a candidate's comments on the Internet (they can obtain our identities on the Internet). Just like driving, our true self shows in how we comment on the Internet.
With how much they missed the latest quarterly earnings, I have little faith in them too. But it's interesting that the average of their seven estimates dropped so much (from $0.37 to $0.26) in one month. I love how you guys like to focus on revenue. The "E" in the PE ratio is earnings, not revenue. About $9.3 million in the Axon revenue in 4Q15 generated a loss of $9 million, the most ever. It's still not in a turnaround mode (minimizing losses), thus delaying the its profitability until at least 2017. How much of your Axon $8M revenue figure gets to the bottom line? How much revenue is necessary to reach break-even in the Axon unit. That's what counts. Axon R&D, which can shrink considerably once developed, was only $0.35 in 2015. Cost of Axon product and service was $0.37 but won't shrink much with higher revenue, so your $0.50 dropping to the bottom line may be aggressive. With the new 2017 average earnings estimate of $0.49, and your estimate is as good as theirs, TASR trades at 38x next year's earnings. Now with the transition to value stocks from growth stocks in the marketplace, TASR is in purgatory with little growth and overvaluation. This is dead money when there are so many other better alternatives to invest in (it's a relative business).
Thank you for your opinion. Now stay on the sidelines and watch. Don't speak, watch. You don't need to keep repeating yourself like robotic Rubio.
The proportionate number will drop significantly now that they will have access to 50 more hospitals come April 1 with CJR. They've increased market share in several locations (from 14 to 22 with greater than 10% and 7 exceeding 15%) and are becoming more vertically integrated bringing more manufacturing in-house, which reduces costs, while increasing prices (a two-fer for improving gross margins). CFMS is the only one with FDA approval for 3D printing with cobalt-molybdenum, the preferred metal combo for these products. And how many patients using off-the-shelf products can go home directly after surgery, saving considerable money for Medicare? Better patient outcomes and satisfaction also a plus. The trend is definitely positive. Let's see how they look in two quarters. They sure beat IBM, which takes two steps backward for every step forward.
Reducing trays of instrumentation to 1 from 10 is a savings. Speeding the implantation process benefits the hospital. Reducing the stay in the hospital to recuperate saves money. The savings are with the customer (doctor/hospital). U.S. Surgical Corporation did the same thing with their minimally-invasive tools for hospitals more than 20 years ago and their stock did a 10-fold increase in the late 1980s and early 1990s. It took a while for their product/service to catch on. That's where CFMS is now.
There is much ado about this accounting VIOLATION. Two CPAs and a sales executive recognized rebate revenue to fend off generic competitors without reporting related costs at the same time over a three-year period. These executives paid fines to settled charges against them. They do not sign off on accounting accuracy on MON's SEC filings. But I wouldn't be surprised if they were let go. When you see accounting gimmickry like this, especially with an S&P 500 company, you know the market is getting near a top. This may be another 2007.
Oh, is that why the price of the iShare NASDAQ Biotech ETF is up only 17% from it 52-week low and down 33% from its 52-week high?
Watch the NYPD camera process to find out. They are looking at dozens of prospects to do cameras, in-house video storage, third-party video storage, or a combination of the two.
You've never heard of litigation financing have you? You fund your legal activity by third-party funding companies and they get a cut of your winnings in court. A small U.K. firm took on Caterpillar Tractor (a David and Goliath situation) and the small firm won $100 million in late 2015. DGLY can do the same thing.
And the restatement news along with his resignation at the SEC's EDGAR service? Accounting gimmickry? CEO's don't leave that quickly without some difference of opinion occurring on how to run the company. You can just see the ambulance-chasing lawyers coming after this company seeking a frustrated investor to be lead plaintiff on a class-action lawsuit. Another company, whose stock priced dropped dramatically in the second half of 2015 due to operational problems, had no less than 19 legal firms seeking class-action lawsuits.